This may also have implications such as the delay of use of immunosuppressive medications as part of the therapeutic management of COVID-19, such as IL-6 inhibitors and the development of antibody therapy which may help to treat both the main viral infection and the immune-neurological logical consequences [20]. This evidence concerns the gene IL6 and viral infectious disease.